PT1077691E - Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same - Google Patents

Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same Download PDF

Info

Publication number
PT1077691E
PT1077691E PT99924164T PT99924164T PT1077691E PT 1077691 E PT1077691 E PT 1077691E PT 99924164 T PT99924164 T PT 99924164T PT 99924164 T PT99924164 T PT 99924164T PT 1077691 E PT1077691 E PT 1077691E
Authority
PT
Portugal
Prior art keywords
gamma
preparing
same
acid derivatives
aminobutyric acid
Prior art date
Application number
PT99924164T
Other languages
Portuguese (pt)
Inventor
Akira Aomatsu
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=15097314&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PT1077691(E) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of PT1077691E publication Critical patent/PT1077691E/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1688—Processes resulting in pure drug agglomerate optionally containing up to 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone

Abstract

1. Technical Result Increase in efficiency of neuropathologic diseases treatment. 2. Essence A pharmaceutical composition containing as an active compound 4-amino-3-substituted-butanoic acid derivative of the general formula NH2 CH2 - C - CH2 COOH R1 R2 wherein the values R1 and R2, have the values indicated in the description, humectants in pharmaceutically effective amount and pharmaceutically acceptable auxiliaries. The composition is obtained by mixing the mentioned compound, humectant and pharmaceutically acceptable auxiliaries. 3. Field of Application Medicine. Tables: 10
PT99924164T 1998-05-15 1999-05-10 Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same PT1077691E (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP13312298A JP3761324B2 (en) 1998-05-15 1998-05-15 Passenger rice transplanter

Publications (1)

Publication Number Publication Date
PT1077691E true PT1077691E (en) 2008-11-04

Family

ID=15097314

Family Applications (1)

Application Number Title Priority Date Filing Date
PT99924164T PT1077691E (en) 1998-05-15 1999-05-10 Gamma-aminobutyric acid derivatives containing, solid compositions and process for preparing the same

Country Status (16)

Country Link
JP (1) JP3761324B2 (en)
CN (1) CN1171587C (en)
AT (1) ATE407668T1 (en)
CA (1) CA2325045C (en)
CY (1) CY1108488T1 (en)
DE (1) DE69939532D1 (en)
DK (1) DK1077691T3 (en)
EA (1) EA006553B1 (en)
EE (1) EE05530B1 (en)
EG (1) EG26287A (en)
ES (1) ES2312208T3 (en)
GE (1) GEP20032987B (en)
IL (2) IL139202A0 (en)
NZ (1) NZ507162A (en)
PT (1) PT1077691E (en)
UA (1) UA76398C2 (en)

Families Citing this family (54)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4904636B2 (en) * 2001-05-29 2012-03-28 井関農機株式会社 Tractor frame
JP5047022B2 (en) * 2008-03-24 2012-10-10 ヤンマー株式会社 Upper and lower split engine storage package connection structure
WO2013008182A1 (en) * 2011-07-10 2013-01-17 Mahesh Kandula Prodrugs of gaba analogs
WO2014037832A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment of epilepsy and neurological diseases
WO2013167985A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurological disorders
WO2013167990A1 (en) 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of depression
EP2847158A4 (en) 2012-05-07 2015-12-30 Cellix Bio Private Ltd Compositions and methods for treatment of neuromuscular disorders and neurodegenerative disorders
WO2013168019A1 (en) * 2012-05-07 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neuropathic pain
US9403826B2 (en) 2012-05-08 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory disorders
US9522884B2 (en) 2012-05-08 2016-12-20 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic disorders
US9434704B2 (en) 2012-05-08 2016-09-06 Cellix Bio Private Limited Compositions and methods for the treatment of neurological degenerative disorders
WO2013168023A1 (en) 2012-05-08 2013-11-14 Mahesh Kandula Compositions and methods for treatment of parkinson's disease
US9309233B2 (en) 2012-05-08 2016-04-12 Cellix Bio Private Limited Compositions and methods for the treatment of blood clotting disorders
US9233161B2 (en) 2012-05-10 2016-01-12 Cellix Bio Private Limited Compositions and methods for the treatment of neurological conditions
US20150087674A1 (en) * 2012-05-10 2015-03-26 Mahesh Kandula Compositions and methods for the treatment of severe pain
WO2013168014A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of familial amyloid polyneuropathy
US9321775B2 (en) 2012-05-10 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of moderate to severe pain
US9346742B2 (en) 2012-05-10 2016-05-24 Cellix Bio Private Limited Compositions and methods for the treatment of fibromyalgia pain
WO2013168015A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of asthma and allergy
US9315478B2 (en) 2012-05-10 2016-04-19 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
WO2013167999A2 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of neurologic diseases
US9242939B2 (en) 2012-05-10 2016-01-26 Cellix Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9339484B2 (en) 2012-05-10 2016-05-17 Cellix Bio Private Limited Compositions and methods for the treatment of restless leg syndrome and fibromyalgia
WO2013168000A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of severe pain
US9403857B2 (en) 2012-05-10 2016-08-02 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9499526B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of neurologic diseases
WO2013168011A1 (en) 2012-05-10 2013-11-14 Mahesh Kandula Compositions and methods for the treatment of chronic pain
WO2013175344A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of periodontitis and rheumatoid arthritis
US9227974B2 (en) 2012-05-23 2016-01-05 Cellex Bio Private Limited Compositions and methods for the treatment of respiratory disorders
US9492409B2 (en) 2012-05-23 2016-11-15 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
JP6202287B2 (en) 2012-05-23 2017-09-27 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of inflammatory bowel disease
JP2015518854A (en) 2012-05-23 2015-07-06 セリックスビオ プライヴェート リミテッド Compositions and methods for the treatment of multiple sclerosis
WO2013175377A2 (en) 2012-05-23 2013-11-28 Mahesh Kandula Compositions and methods for the treatment of mucositis
US9108942B1 (en) 2014-11-05 2015-08-18 Mahesh Kandula Compositions and methods for the treatment of moderate to severe pain
WO2014020480A2 (en) 2012-08-03 2014-02-06 Mahesh Kandula Compositions and methods for the treatment migraine and neurologic diseases
WO2014037833A2 (en) 2012-09-06 2014-03-13 Mahesh Kandula Compositions and methods for the treatment inflammation and lipid disorders
CA2873029A1 (en) 2012-09-08 2014-03-13 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and lipid disorders
US9333187B1 (en) 2013-05-15 2016-05-10 Cellix Bio Private Limited Compositions and methods for the treatment of inflammatory bowel disease
CA2914461A1 (en) 2013-06-04 2014-12-11 Cellixbio Private Limited Compositions and methods for the treatment of diabetes and pre-diabetes
US9096537B1 (en) 2014-12-31 2015-08-04 Mahesh Kandula Compositions and methods for the treatment of mucositis
CA2976314C (en) 2014-09-26 2021-02-23 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy and neurological disorders
JP6698643B2 (en) 2014-09-29 2020-05-27 セリックス バイオ プライヴェート リミテッドＣｅｌｌｉｘ Ｂｉｏ Ｐｒｉｖａｔｅ Ｌｉｍｉｔｅｄ Compositions and methods for the treatment of multiple sclerosis
CN104352476A (en) * 2014-10-21 2015-02-18 齐宏 Gabapentin capsule and preparation method thereof
WO2016098119A1 (en) 2014-10-27 2016-06-23 Cellix Bio Private Limited Three component salts of fumaric acid monomethyl ester with piperazine or ethylene diamine for the treatment of multiple sclerosis
US9175008B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Prodrugs of anti-platelet agents
US9321716B1 (en) 2014-11-05 2016-04-26 Cellix Bio Private Limited Compositions and methods for the treatment of metabolic syndrome
US9290486B1 (en) 2014-11-05 2016-03-22 Cellix Bio Private Limited Compositions and methods for the treatment of epilepsy
US9150557B1 (en) 2014-11-05 2015-10-06 Cellix Bio Private Limited Compositions and methods for the treatment of hyperglycemia
US9173877B1 (en) 2014-11-05 2015-11-03 Cellix Bio Private Limited Compositions and methods for the treatment of local pain
US10208014B2 (en) 2014-11-05 2019-02-19 Cellix Bio Private Limited Compositions and methods for the treatment of neurological disorders
US9284287B1 (en) 2014-11-05 2016-03-15 Cellix Bio Private Limited Compositions and methods for the suppression of carbonic anhydrase activity
US9932294B2 (en) 2014-12-01 2018-04-03 Cellix Bio Private Limited Compositions and methods for the treatment of multiple sclerosis
US9206111B1 (en) 2014-12-17 2015-12-08 Cellix Bio Private Limited Compositions and methods for the treatment of neurological diseases
EP3242869B1 (en) 2015-01-06 2021-10-27 Cellixbio Private Limited Compositions and methods for the treatment of inflammation and pain

Also Published As

Publication number Publication date
CN1300213A (en) 2001-06-20
ATE407668T1 (en) 2008-09-15
DE69939532D1 (en) 2008-10-23
EG26287A (en) 2013-06-12
NZ507162A (en) 2003-11-28
CN1171587C (en) 2004-10-20
GEP20032987B (en) 2003-06-25
EA006553B1 (en) 2006-02-24
CY1108488T1 (en) 2014-04-09
CA2325045A1 (en) 1999-11-25
ES2312208T3 (en) 2009-02-16
EA200001154A1 (en) 2001-06-25
DK1077691T3 (en) 2008-10-27
EE200000671A (en) 2002-04-15
IL139202A (en) 2014-12-31
CA2325045C (en) 2005-05-03
JPH11318133A (en) 1999-11-24
EE05530B1 (en) 2012-04-16
JP3761324B2 (en) 2006-03-29
IL139202A0 (en) 2001-11-25
UA76398C2 (en) 2006-08-15

Similar Documents

Publication Publication Date Title
IL139202A0 (en) Solid compositions containing gamma-aminobutyric acid derivatives and process for preparing the same
BR9510168A (en) Polyamino acid compound composition unit dosage form and method for preparing a composition
GEP20033131B (en) Azabicycloalkanes as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Activity
GEP20043161B (en) Piperidines as CCR5 Modulators, Pharmaceutical Compositions Containing the Same and Their Use for Treatment and Prevention of Diseases Caused by CCR5 Modulators
MY129473A (en) 3,3-diarylpropylamines, their use and preparation
AU4950096A (en) Esters of 5-aminolevulinic acid as photosensitizing agents in photochemotherapy
GEP20002298B (en) Benzimidazole Derivatives, Method of Their Production, Pharmaceutical Composition Containing the Same and Method for Its Treatment
GEP20043237B (en) Pyrazoline Derivatives, Method for Their Preparation and Compositions Containing Them for Treatment of Diseases Mediated by Cyclooxygenase-2
GEP20033079B (en) Pharmaceutical Compositions for Treatment of Diseases Caused by Estrogens Deficiency
GEP20022654B (en) Indazole Amide Compounds As Serotoninergic Agents
RU94046044A (en) NEW 7β-SUBSTITUTED 4-AZA-5a-CHOLESTAN-ONES AS INHIBITORS OF 5a-REDUCTASE, PHARMACEUTICAL COMPOSITION BASED ON THEREOF, METHOD OF ITS PREPARING
ATE84045T1 (en) INHIBITING SUBSTANCES ENKEPHALINASE-B THEIR PREPARATION AND THEIR PHARMACEUTICAL COMPOSITIONS.
EP0398720A3 (en) Piperazine derivatives
UA42733C2 (en) Bis-naphthalimide derivatives and pharmaceutically acceptable acid addition salts thereof, pharmaceutical composition containing them showing cytotoxic activity
TR199801229T2 (en) "Thiol derivatives with metalopeptidase inhibition activity"
HUT70531A (en) Arylmorpholine derivatives, pharmaceutical compositions containing them as active agent and process for preparing them
GEP19991872B (en) Novel Taxoids, Preparations Thereof, and Pharmaceutical Compositions Containing Same
CA2438509A1 (en) Use of cyclohexenone derivatives for the manufacture of a medicament in the treatment of dysuria
RU98103388A (en) (R) -5-BROM-N- (1-ETHYL-4-Methylhexagidro-1H-1,4-Diazepin-6-IL) -2-METHOXI-6-M COMPOSITION CONTAINING THE SPECIFIED CONNECTION
GEP19991869B (en) Amino Acid Derivatives of Substituted Quinoxaline 2,3-Dione Derivatives as Glutamate Receptor Antagonists
CA2202904A1 (en) Pharmaceutical composition for prophylaxis and treatment of type i allergic diseases
ES2005042A6 (en) Anticonvulsant composition containing amino acid derivative and use of said amino acid derivative.
HU903092D0 (en) Process for the preparation of buten-carboxylic acid derivatives and pharmaceutical compositions containing such compounds
CA2263184A1 (en) Methods and compositions for increasing the anaerobic working capacity in tissues
HU194809B (en) Process for producing acyl-enamide compounds and pharmaceutical compositions containing them as active components